Compass Therapeutics (US.CMPX)
资本配置审计 · 期间： 2018 – 2026
核心指标
US.CMPX · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.8% | → |
| ROE | -26.2% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.06 | ↑ |
| Gross Margin | - | → |
US.CMPX (Compass Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.8% → ROE -26.2% ↑ Cash Conversion - → D/E Ratio 0.06 ↑ Gross Margin - →
核心指标
US.CMPX (Compass Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.8% →ROE -26.2% ↑Cash Conversion - →D/E Ratio 0.06 ↑Gross Margin - →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies